SomaLogic, Inc., a global leader in proteomics technology, announced today that it is adding to its list of collaborative agreements with global healthcare innovator, Novo Nordisk. As part of the agreement, Novo Nordisk will expand the use of the SomaScan® technology platform for their drug development research in non-alcoholic steatohepatitis (NASH), cardiovascular disease and diabetes.
SomaLogic, Inc., a global leader in proteomics technology, announced today that their new customizable protein panel products are now available to pharma, biotechnology and academic research customers seeking the power of the company’s proteomics menu of 7,000 proteins.
SomaLogic launches the SomaSignal™ Proteomics for Precision Medicine Initiative with healthcare innovators: Emory University, Intermountain Healthcare, CommonSpirit Health and UCHealth
SomaLogic announced today its SomaSignal™ Proteomics for Precision Medicine Initiative, the first large-scale, clinically focused partnership effort aimed at equipping healthcare providers with the power of proteomic technology to inform decisions at the point of care.
Researchers at the University of Cambridge report the largest, systematic assessment of two different affinity-based proteomic platform technologies to date. By truncating the 5000-plex aptamer-based SomaScan® Assay results down to consider approximately 900 overlapping targets on a polyclonal antibody-based assay and running both assays on the same 485 genotyped samples, the researchers successfully replicated most proteogenomic signals on both platforms.
The Colorado BioScience Association (CBSA) recently announced that SomaLogic Chief Executive Officer Roy Smythe was among the seven new members appointed to its board of directors. These new members were selected for their leadership at companies of all stages of commercialization and have expertise in issues that impact Colorado’s life sciences community.
Dr. Larry Gold, the founder of SomaLogic, was awarded the Lifetime Achievement Award on behalf of the International Society on Aptamers (INSOAP) for his pioneering and extraordinary contributions to the field of aptamers and therapeutics.
SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform
SomaLogic and CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction CM Life Sciences II will be renamed and its common stock will be listed on the Nasdaq Global Market under ticker symbol “SLGC.”
SomaLogic, Inc., a global leader in proteomics technology, announced today its intention to broaden its proteomics offerings to pharma, biotechnology and academic research customers by adding smaller protein measurement panel products to its market-leading, large-plex offering.
SomaLogic Inc. today announced the appointment of Jason Cleveland, Ph.D. as the company’s chief technology officer. In this role, Dr. Cleveland will drive technological innovations that will bring the SomaScan® proteomics platform to patients around the world.
SomaLogic Inc. announced today the appointments of Angela Bakker Lee, Ph.D. as executive vice president for healthcare markets, Tracy Hervey, MBA as executive vice president for life sciences markets and David McGovern, MBA as senior vice president of marketing. In these roles, Dr. Bakker Lee, Ms. Hervey and Mr. McGovern will drive business development and marketing efforts for SomaLogic’s proprietary protein measurement technology and growing portfolio of protein-based health information products.